Investigators enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total body irradiation or reduced intensity with fludarabine/melphalan.
[Blood Advances]
7992332
{7992332:9QHMQRUP}
apa
50
1
163752
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/